Cargando…
Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy
Brolucizumab is a novel humanised, single-chain, variable fragment inhibitor of Vascular Endothelial Growth Factor-A for the treatment of neurovascular age-related macular degeneration. Brolucizumab gained US Food and Drug Administration and European Medicines Agency approval following the Phase III...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892069/ https://www.ncbi.nlm.nih.gov/pubmed/35102497 http://dx.doi.org/10.1007/s11845-022-02929-8 |